Elisabetta Bonzano, Medical Director and Radiation Oncologist at IRCCS San Matteo Polyclinic Foundation, shared a post on X about a paper by Luca Visani et al. published in The Breast:
“Concomitant radiation therapy and trastuzumab deruxtecan in metastatic breast cancer: feasibility, safety, and outcomes from a real-life multicentre international cohort.
- Largest multicentre cohort on concomitant T-DXd and radiation therapy in breast cancer.
- Concomitant treatment showed no increase in severe or treatment-limiting toxicity.
- Permanent T-DXd discontinuation rates were similar with or without radiation therapy.
- One case of symptomatic radionecrosis after intracranial radiation therapy (1.5%).
- Findings support the feasibility of concurrent T-DXd + RT, warranting prospective trials.”
Title: Concomitant radiation therapy and trastuzumab deruxtecan in metastatic breast cancer: feasibility, safety, and outcomes from a real-life multicentre international cohort
Authors: Luca Visani, Ivica Ratosa, Rupert Bartsch, Barbro Linderholm, Gaia Griguolo, Calogero Saieva, Carlotta Becherini, Marianna Valzano, Viola Salvestrini, Angelika M. Starzer, Peter Kus, Niccolò Bertini, Andrea Rampini, Chiara Mattioli, Domen Ribnikar, Jacopo Nori Cucchiari, Lorenzo Orzalesi, Simonetta Bianchi, Matteo Lambertini, Valentina Guarneri, Lorenzo Livi, and Icro Meattini.
You can read the Full Article in The Breast.
More posts featuring Elisabetta Bonzano.